glp-1 ckd receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Glucagon-like peptide-1 receptor agonists in
Description
Grains High-fiber grains, when fermented in the gut, produce short-chain fatty acids (SCFAs)
Hypoglycemia Increased heart rate Potential pancreatitis Gallbladder issues Acute kidney injury Risk of thyroid tumors It is recommended that patients be monitored for these risks, especially those with a history of thyroid disease
[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Cunningham LL, Tucci DL
When you're already dealing with reduced appetite from GLP-1s, this might seem counterintuitive
Most patients notice reduced appetite within the first few weeks, with steady weight loss occurring over several months
Gong N, Xiao Q, Zhu B, et al
